ProteoNic Biosciences, a leader in vector technology and services for biologics production, has announced a partnership with Ginkgo Bioworks, known for its advancements in cell programming and biosecurity. This collaboration aims to provide Ginkgo Bioworks' clients access to ProteoNic's vector technology for protein production and viral vector technology for cell and gene therapy applications. ProteoNic will also join the Ginkgo Technology Network, a platform that brings together various technology partners to drive innovation in customer R&D programs.

Frank Pieper, CEO of ProteoNic, stated, "This partnership aligns with our mission of supporting clients in biologics manufacturing and addressing challenges in viral vector manufacturing for cell and gene therapies."

ProteoNic's vector technology is versatile, applicable across cell lines and product types, including complex molecules traditionally difficult to produce. It aims to improve production efficiency, overcome capacity constraints, and reduce manufacturing costs, particularly in viral vector production.

The Ginkgo Technology Network integrates partners from AI, genetic medicines, biologics, and manufacturing to offer comprehensive solutions for R&D. Anna Marie Wagner, Ginkgo's SVP, Head of AI, and Corporate Development, expressed excitement about ProteoNic joining the network, highlighting their expertise and premium technology's value to customers in various biotech sectors.

 

Source: prnewswire.com

Report Abuse